Morgan Stanley Sticks to Its Buy Rating for Samvardhana Motherson International Limited (MOTHERSON)
Morgan Stanley analyst Binay Singh maintained a Buy rating on Samvardhana Motherson International Limited (MOTHERSON – Research Report) on May 30 and set a price target of INR183.00. The company's shares closed last Friday at INR153.12.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Singh is a 2-star analyst with an average return of 1.9% and a 63.64% success rate. Singh covers the Consumer Cyclical sector, focusing on stocks such as Bajaj Auto Limited, Eicher Motors Limited, and Hero Motocorp Limited.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Samvardhana Motherson International Limited with a INR154.67 average price target, a 1.01% upside from current levels. In a report released on May 30, CLSA also maintained a Buy rating on the stock with a INR182.00 price target.
The company has a one-year high of INR217.00 and a one-year low of INR107.30. Currently, Samvardhana Motherson International Limited has an average volume of 1.09M.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Ulta Beauty Stock (ULTA) Maintains Bold Comeback Following Q1 Beat
After a rocky couple of years, Ulta Beauty (ULTA) is staging a fierce comeback, with its stock surging and its investment case looking increasingly better by the quarter. Evidently, the company's Q1 results posted just last week lit a spark under the stock, showcasing robust comparable sales growth, strategic wins, and an aggressive share buyback program. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Despite its recent rally, I believe Ulta Beauty still offers attractive value, making it a compelling choice for long-term investors. Here's why I remain bullish on the stock. Walking into an Ulta store these days feels like stepping into a bustling beauty bazaar, and the numbers certainly back up that vibe. In Q1, Ulta reported a 2.9% increase in comparable sales, blowing past Wall Street's modest expectations of just 0.2% growth. This uptick, driven by a 2.3% rise in average ticket size and a 0.6% increase in transactions, shows Ulta is pulling customers back in a big way, even in the face of the brutal competition facing the beauty industry these days. Under new CEO Kecia Steelman, the company's 'Ulta Beauty Unleashed' plan is resonating, with fresh promotions and a beefed-up loyalty program, now boasting a record 44.6 million members and keeping shoppers hooked. One could argue that this is a one-quarter fluke. However, Ulta's focus on exclusive products and in-store experiences, like their expanded Target shop-in-shops, is undeniably driving traffic. There is no reason to think that this trend will fade soon, especially since Ulta is coming off some difficult quarters (hence the stock's underperformance in 2024), and the recent numbers indicate that a proper rebound has now been established. To be frank, the company's ability to outpace estimates in such a tough retail environment (particularly competition-wise) signals a consumer base that's still willing to splurge on beauty, even during a period of economic uncertainty. One of the more interesting takeaways from Ulta's report is that the company isn't solely relying on its core business to drive growth, but is instead exploring new opportunities. During the earnings call, executives talked about plans to expand into Mexico and the Middle East this year. They've already opened six new stores this quarter, bringing their total to 1,451, after adding 100 Ulta Beauty stores at Target locations last year. Interestingly, these moves don't necessarily seem to be about expanding square footage (as is the case with retailers), but rather about making Ulta a go-to destination for beauty lovers everywhere. Then there's the loyalty program, which grew 3% last year to the 44.6 million mark. It's a sticky ecosystem that keeps customers coming back, and Ulta is doubling down with digital upgrades and personalized marketing. When you pair these efforts with exclusive brand launches, you can see how Ulta can claw back market share from competitors like Sephora and Amazon, even as those giants loom large. Ulta has a tremendous track record of share repurchases. It has essentially been using the majority of its free cash flow over the years to repurchase as many shares as possible. For context, over the past decade, Ulta has reduced its share count by 30%. In Q1, this trend endured, with Ulta repurchasing $249.5 million worth of stock. With $2.7 billion still available under their $3 billion program, Ulta is signaling confidence in its future and the stock's present valuation. I love seeing a company bet on itself like this. Management is like they're saying, 'We know we're undervalued, and we're not afraid to prove it.' Regarding Ulta's valuation, even after the stock's post-earnings rebound, it's still trading at just 20x this year's expected EPS. Considering that sales are on the rebound, margins are stabilizing, and buybacks are continually reducing the share count, EPS growth is expected to pick up in the coming years. In fact, repurchasing shares at today's valuation is likely to prove exceptionally accretive in the long term. Therefore, I believe that the current multiple undervalues Ulta's medium-term prospects. Despite the stock's recent rebound, Wall Street remains optimistic about Ulta. The stock still features a Moderate Buy consensus rating, with 12 analysts currently bullish, 12 neutral, and just one bearish. Now, Ulta's average stock forecast of $470.04 indicates marginal downside potential over the coming twelve months. Ulta Beauty appears to be regaining its momentum. The company delivered strong comparable sales, executed key strategic initiatives, and continues to return value to shareholders through a robust buyback program. Trading at roughly 20 times earnings, Ulta offers a compelling blend of value and growth—an uncommon combination in the often-volatile retail sector. With a meaningful margin of safety and solid upside potential, the stock presents a highly attractive investment opportunity at current levels. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
GLP-1 users taking drugs like Ozempic and Wegovy are spending less on eating at restaurants and on take-out dinners, according to a new report from Bloomberg Intelligence. Changing eating habits add to a growing number of headwinds the hospitality industry is facing as a result of slow pandemic recovery and tariff-induced economic uncertainty. As restaurants grapple with how diners are responding to economic uncertainty, they may also have to contend with consumer pull-backs as a result of the rise of drugs like Ozempic and Wegovy. GLP-1 users are significantly cutting back on dining in and ordering takeout, according to a report published this week by Bloomberg Intelligence. A survey of 1,000 GLP-1 users in the U.S. found 54% of respondents said they dined out 'significantly less' or 'less' frequently since starting the medication. Nearly the same percentage reported ordering less take-out. Respondents instead are choosing to eat at home, with 70% of them reporting they're cooking at home 'significantly more' or 'more' frequently since taking GLP-1 drugs, and about half reported purchasing more groceries. GLP-1 drugs, with the ability to help some users lose weight quickly, have skyrocketed in popularity. About 4% of Americans are taking some form of GLP-1 drug for weight-loss or to treat type 2 diabetes, a 600% increase in usage from six years ago, according to May data from FAIR Health. The drugs increase insulin levels and decrease glucose levels, slowing how quickly food is digested and suppressing users' appetites. Suppressed hunger has led to some users cutting down portion sizes or needing to focus on eating nutrient-dense foods, which may deter them from dining in restaurants. Bloomberg Intelligence's research adds to growing evidence of GLP-1 users losing their appetite for dining out. A Morgan Stanley survey from April 2024 found nearly two-thirds of GLP-1 users said they spent less money at restaurants, while 31% said they cut back on groceries. The trends have led to some food companies making changes to products to account for GLP-1 users' changing appetites. In October 2024, Smoothie King added a line of high-protein and fiber products particularly for those on the medication. The year before, Nestle announced it would develop 'companion products' for GLP-1 users, should those consumers need to cut calories. GLP-1 drugmakers have taken note of some companies' anxiety. In February 2024, Lars Fruergaard Jørgensen, the CEO of Ozempic-maker Novo Nordisk, said he was fielding calls from 'scared' food company executives about the impact of the drug on the industry. The Bloomberg Intelligence report notes the dining out slowdown among GLP-1 users could be exacerbated by other economic pressures. The decrease in away-from-home dining was reported significantly across incomes, from those earning less than $50,000 to those with $150,000 or greater annual salaries, indicating a broader shift in dining trends. The report also posited that restaurants serving fewer healthy options like fast-food could be most impacted by changing eating habits. Indeed, it's not just evolving dining habits that the restaurant industry has had to contend with. The hospitality sector has had to navigate the impact of greater economic headwinds, including a widespread labor shortage that never quite recovered from the pandemic, as well as growing uncertainty about tariffs, which have led consumers confidence to plunge. Campbell's CEO Mick Beekhuizen said in an earnings call this week canned soup sales are soaring, likely a result of tighter food budgets and consumers deciding to cook at home instead of going out to eat. 'We started to see consumer sentiment softening in January,' he said. 'This continued throughout [the quarter] with consumers making more deliberate choices with their spending on food. A key outcome is a growing preference for home-cooked meals, leading to the highest levels of meals prepared at home since early 2020.' Hospitality industry experts have noted that Gen Z is also cutting back on their order sizes bysplitting appetizers, ordering kids' meals, and skipping out on alcohol to save money. Despite evidence that GLP-1 users are significantly cutting back on restaurant dining, some restaurateurs have shrugged off concerns about the drug's impact on business. Michael Osanloo, president and CEO of Portillo's Restaurant Group told Bloomberg TV last year GLP-1 use taking a bite out of the restaurant business could be a coastal problem, not one for the U.S. Midwest. 'It's totally overblown,' Osanloo said. 'I think it's a fun narrative to propose, but I don't see any impact on our business.' This story was originally featured on
Yahoo
7 hours ago
- Yahoo
TSMC Defies Gruesome Geopolitical Odds With Friends in High Places
As an avid follower of semiconductor stocks, I'm genuinely excited by the recent momentum in Taiwan Semiconductor Manufacturing Company (TSM), widely known as TSMC. The stock has decisively broken above its key 50-week moving average—a technical milestone that's hard to overlook. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter However, my optimism extends far beyond chart patterns. TSMC is a pivotal force at the heart of the AI revolution, playing a crucial role in powering next-generation technologies. The company is aggressively expanding its global footprint with major facilities planned across Europe, the U.S., and most intriguingly, the United Arab Emirates. For investors who recognize the strategic significance of technological leadership, TSMC is far more than just another chipmaker—it's a cornerstone of global economic and national security. Given the confluence of positive factors surrounding TSMC stock, I'm confidently bullish on its chances of picking its way through the brewing geopolitical minefield to, ultimately, deliver strong shareholder returns for the next decade. From a financial standpoint, TSMC's performance in Fiscal 2025 has been nothing short of exceptional. In the first quarter alone, revenue surged by 35% year-over-year, reaching approximately $25.5 billion. This impressive growth has been fueled by strong and timely demand from high-performance computing and automotive sectors, more than offsetting temporary softness in the smartphone market. Notably, TSMC's cutting-edge 3-nanometer process has become a meaningful contributor to revenue, further underscoring the company's leadership in advanced semiconductor manufacturing. Despite facing some operational headwinds, including an early-year earthquake, TSMC has maintained robust profitability. Non-GAAP gross margins came in at around 59%, significantly beating analysts' subdued expectations. Management also remains highly optimistic about the near-term outlook, guiding for another strong quarter with an anticipated 38% year-over-year revenue increase in Q2. Altogether, this powerful blend of rapid growth and resilient profitability signals that TSMC is far more than a cyclical beneficiary. It is a foundational force in the global tech ecosystem, building lasting competitive moats and firmly establishing itself as the dominant player in semiconductor manufacturing. I've taken a deep interest in TSMC's bold and rapidly unfolding global expansion strategy. The company's landmark $100 billion investment in Arizona represents more than just a manufacturing footprint—it signals a decisive pivot by the U.S. toward strengthening domestic semiconductor resilience. While challenges such as elevated labor costs and project delays are to be expected, the long-term strategic value is substantial. This initiative cements TSMC as a foundational technology partner for the West and a central pillar of the emerging U.S. semiconductor ecosystem. Equally impressive is TSMC's growing presence in Europe. Its joint venture in Dresden, Germany—alongside Bosch, Infineon (IFNNY), and NXP Semiconductors (NXPI)—marks a transformative effort to reshape the continent's semiconductor supply chain. With a total project cost of approximately €10 billion, half of which is backed by EU state aid, the partnership aims to reduce Europe's reliance on external sources for advanced chips. This move is not only strategically sound but also enhances TSMC's global resilience and influence. Perhaps the most intriguing development is the proposed 'gigafab' in the United Arab Emirates. TSMC is reportedly in discussions with Abu Dhabi's sovereign wealth fund, Mubadala, which, if finalized, would signal a breakthrough expansion into the rapidly evolving tech ambitions of the Middle East. Though still speculative, this potential partnership could significantly extend TSMC's geopolitical reach and strategic footprint. Altogether, TSMC's global initiatives reflect a visionary approach to navigating complex geopolitical and economic terrains. These moves aren't just about scaling production—they're about redefining the global semiconductor map, securing long-term relevance, and reinforcing TSMC's status as a trailblazer in advanced manufacturing. Technically speaking, TSMC's recent price action represents an undeniably eye-popping bull pattern, drawing tremendous interest from institutional investors. The technical indicators, such as the Relative Strength Index, down in the mid-60s, suggest that TSMC has plenty of room for continued gains before becoming overbought. In fact, even heavyweights such as Cathie Wood's ARK Invest have recently increased their holdings in TSMC. This adds another dimension of institutional confidence that deserves the attention of retail investors. For me, the institutional dynamics tell a strong story about why TSMC will continue to compound returns impressively. That said, while I remain optimistic about TSMC's long-term prospects, the geopolitical risk surrounding China and Taiwan is both real and significant. The increasing military activity by China's People's Liberation Army in the Taiwan Strait cannot be overlooked. According to various intelligence reports, China is preparing for potential scenarios involving Taiwan, with a key timeline centered around 2027. Should a military conflict occur, the consequences for TSMC would be severe. Its critical manufacturing facilities could face operational disruptions or even destruction, triggering a major shock to the global semiconductor supply chain. Based on my analysis, such an event could lead to a collapse in TSMC's stock price, potentially as much as 60%. Given the scale of this risk, it demands careful consideration. Even with a fundamentally bullish outlook, I believe it's essential to have a clear risk-management strategy in place. This is not about fear—it's about being realistic in the face of a complex and evolving geopolitical landscape. On Wall Street, TSMC stock holds a consensus Strong Buy rating, supported by seven Buy ratings, one Hold, and zero Sells. TSMC's average stock price target sits at $219.43, suggesting a potential upside of 13% over the next 12 months. Personally, I'm a bit more bullish, with my own price target closer to $250. Overall, I remain firmly bullish on TSMC. This investment goes beyond financials—TSMC is a cornerstone of the global technology infrastructure. While the geopolitical risk tied to its location in Taiwan is both real and substantial, it's a factor that strategic investors must weigh carefully. For those capable of evaluating the balance between opportunity and geopolitical exposure, TSMC presents a rare and compelling proposition. Given the company's dominant market position and long-term growth potential, my $250 price target feels not only reasonable but well within reach. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
